Skip to main content

Day: March 23, 2023

Parsons Accelerating Clean Energy Technology Through Department of Energy Contract Award

CENTREVILLE, Va., March 23, 2023 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was selected by the U.S. Department of Energy (DOE) Office of Clean Energy Demonstrations (OCED) to accelerate clean energy technologies from the lab to market. The new $14 million ceiling-value task order contract includes a one-year base period with two option period years and was awarded under the National Nuclear Security Administration (NNSA) Enterprise Construction Management Services contract that the company was awarded in June 2022. OCED was established in December 2021 with over $25 billion provided by the Infrastructure Investment and Jobs Act (IIJA) and the Inflation Reduction Act (IRA) for large-scale clean energy demonstration projects, filling a critical innovation gap on the path to achieving the...

Continue reading

Form 8.3 – [Devro plc – 22 03 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree DEVRO PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline. “We have completed a transformational 2022 for Cidara and are carrying that momentum into 2023 with the recent U.S. Food and Drug Administration (FDA) approval of rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options. This approval enables Cidara to receive a $20.0 million regulatory milestone payment under the terms of our agreement with Melinta Therapeutics,”...

Continue reading

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, Including Positive Sorbitol Reduction Data from the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency On Track to Report Additional Phase 3 Data Across Multiple Programs in 2023 NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2022. “We are pleased with the clinical progress in 2022 across all three of our registrational Phase 3 programs, and we look forward to the data readouts in the year ahead,” said Shoshana Shendelman, PhD, Founder and CEO...

Continue reading

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors Following the expected Q2 2023 closing of the all-stock transaction, the combined company’s cash runway is expected to extend into 2026CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) — TCR² Therapeutics Inc. (Nasdaq: TCRR) (TCR² or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced fourth quarter and full-year 2022 financial results and provided a corporate update. “Focus and specialization are critical in the cell therapy space. The strategic combination with Adaptimmune and the operating benefits are highly compelling for both Adaptimmune and TCR² shareholders. Our complementary...

Continue reading

Affimed Reports 2022 Financial Results and Operational Progress

AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023 AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meeting AFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023 AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four European countries including Belgium, France, Denmark and Spain Anticipated cash runway into 2025: As of December 31, 2022, cash and cash equivalents were €190.3 millionHEIDELBERG, Germany, March 23, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results...

Continue reading

Creative Realities, Inc. Announces Year End 2022 Earnings Release Date and Conference Call Information

LOUISVILLE, Ky., March 23, 2023 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “company”) (NASDAQ: CREX, CREXW), a leading provider of digital signage solutions, announced today that it will release its financial results for the year ended December 31, 2022 before the market open on Thursday, March 30, 2023. A conference call to review the results is scheduled for Thursday, March 30, 2023 at 9:00 am Eastern Time, which will include prepared remarks from management followed by a live Q&A. The call will be hosted by Rick Mills, Chief Executive Officer, and Will Logan, Chief Financial Officer. Prior to the call, participants should register at bit.ly/CRIearnings2022Q4. Once registered, participants can use the weblink provided in the registration email to participate...

Continue reading

Psyence Group Announces Cantheon Capital Private Placement

VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that it has entered into a brokered subscription agreement with Cantheon Capital, LLC (“Cantheon”). Cantheon, a fund focussed on listed biotech stocks with near term catalysts, will invest an aggregate amount of USD $1,393,750 (payable in two equal tranches) to fund Psyence’s clinical trial in Australia, which will be conducted through recently announced Contract Research Organization (CRO) partner iNGENū Pty Ltd. (“iNGENū”).   The proceeds from the subscription will help fund the design and conduct of Psyence’s Phase IIb clinical trial using a natural psilocybin drug...

Continue reading

LGI Homes Announces Grand Opening of New Community Near Atlanta

The Lincoln Plan by LGI Homes at Avondale North features four bedrooms, two and a half bathrooms and a game room. LGI Homes announces the grand opening of Avondale North in Conyers, a community of new, move-in ready homes with designer upgrades included.CONYERS, Ga., March 23, 2023 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ:LGIH) today announced the opening of a new community in the Atlanta, Georgia market, Avondale North. Avondale North by LGI Homes is located in Conyers, a quaint town on the southeast side of Atlanta. Here, homeowners will enjoy exploring the small town atmosphere, as well as the surrounding areas. Just ten minutes from the community is Old Town Conyers, an entertainment district and popular TV show filming site. Homebuyers will enjoy all of this while still having easy access to downtown Atlanta. LGI Homes...

Continue reading

Castellum, Inc. Announces Closing of GTMR Acquisition

Castellum, Inc. Announces Closing of GTMR Acquisition Castellum, Inc. (NYSE-American: CTM), a cybersecurity and electronic warfare services company focused on the federal government, announces that it has closed its previously announced acquisition of Global Technologies Management Resources, Inc. (“GTMR”), a $10 million revenue government contractor based in Hollywood, Maryland near Naval Air Station Patuxent River – http://castellumus.com/BETHESDA, Md., March 23, 2023 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM), a cybersecurity and electronic warfare services company focused on the federal government, announces that it has closed its previously announced acquisition of Global Technologies Management Resources, Inc. (“GTMR”), a $10 million revenue government contractor based in Hollywood, Maryland near Naval...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.